AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries

RecruitingPhase 3Ages 18 Years - 49 YearsFemaleNICHD Global Network for Women's and Children's Hโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study, Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (ABLE), is designed as a 2-arm randomized controlled trial (RCT) focused on pregnant individuals and newborn infants. A positive outcome of this study will contribute to global progress toward WHO Sustainable Development Goal Target 3.2 \[End preventable deaths of newborns and children under 5 years of age\] by examining the potential impact of this practice to reduce the incidence of SVN/SB and the lifelong health consequences associated with SVNs. In addition, the study will further explore the role and potential benefits of antibiotic treatment of AB in the pregnant individual. In total, 1,134 eligible participants, or approximately 162 per research site, will be randomized in the trial by the research teams in each of the seven international sites that, together with their United States of America (

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Individuals who meet the following criteria are eligible for randomization: * Enrolled in GN MNHR * Established pregnancy โ‰ฅ12 and โ‰ค20 weeks GA by last menstrual period and/or clinical assessment and/or ultrasonography * Age: 18 years (or lower limit age eligible\*) to 49 years \* Some sites will be able to include individuals giving birth regardless of age if they are considered an adult or an emancipated minor. However, other sites will require individuals to be at least 18 years of age. The investigators will adhere to local regulations. * Expressed understanding of study procedures and willingness to complete screening, randomization, study drug administration and follow-up * Able to provide informed consent * Presence of a single bacterial isolate (\>105 colony forming unit (CFU)/mL) in urine at enrollment * Intent to remain in study area for at least 42 days PP Exclusion Criteria: Individuals who meet any of the following criteria are not eligible for randomization: * Gestational age \<12 weeks or \>20 weeks * Received treatment with any antibiotic within 14 days before screening visit * Current symptoms of UTI * History of allergy to nitrofurantoin * Pregnancy loss / miscarriage prior to randomization * Currently taking magnesium-containing antacid * Any illness / condition (e.g., anemia, diabetes, renal disease, pulmonary disease) requiring immediate medical care per site PI assessment * Enrollment in another trial that per the study MOP will impact this trial
๐Ÿ’Š

What it tests

  • Oral nitrofurantoin monohydrate/macrocrystals
  • Placebo
๐Ÿ“

Where

7 sites
Icddr,B
Dhaka, Bangladesh
Kinshasa School of Public Health
Kinshasa, Democratic Republic of the Congo
Institue for Nutrition of Central America and Panama (INCAP)
Guatemala City, Guatemala
KLE Academy of Higher Education and Research
Belagavi, India
Lata Medical Research Foundation
Nagpur, India
Aga Khan University
Karachi, Pakistan
University Teaching Hospital
Lusaka, Zambia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy